Literature DB >> 6790656

Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo.

C Hardt, M Röllinghoff, K Pfizenmaier, H Mosmann, H Wagner.   

Abstract

Sera of thymus-bearing normal mice contain high levels of Interleukin 2 (II-2) inhibitor, whereas sera of athymic nu/nu mice do not. Evidence is presented that cyclophosphamide-sensitive Lyt-23+ T cells induce high II-2 inhibitor activity in the recipient nu/nu mice in the course of a graft-vs.-host reaction. The II-2 inhibitor has an approximately 50,000 mol wt. Its function is neither antigen specific nor H-2 restricted. During ontogeny, its activity parallels the development of T cell reactivity, i.e., it is absent both in the amniotic fluid and in sera of unborn mice, but increases to high levels during the early postnatal phase. The II-2 inhibitor described is viewed as an example of a T cell-dependent, in vivo regulatory mechanism able to effectively counteract the nonspecific activity of the Lyt-1+ helper T cell-derived II-2. Because the II-2 inhibitor activity is rather high in vivo, II-2 activity will exist only in close proximity to its producer cell, thereby maintaining specificity during the in vivo induction of cytotoxic T lymphocytes

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6790656      PMCID: PMC2186429          DOI: 10.1084/jem.154.2.262

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells.

Authors:  K Pfizenmaier; A Starzinski-Powitz; M Röllinghoff; D Falks; H Wagner
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

2.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Antigen-induced selective recruitment of circulating lymphocytes.

Authors:  J Sprent; J F Miller; G F Mitchell
Journal:  Cell Immunol       Date:  1971-04       Impact factor: 4.868

5.  Effect of normal mouse serum on mouse lymphocyte transformation in vitro.

Authors:  D S Nelson; C N Shneider
Journal:  Eur J Immunol       Date:  1974-02       Impact factor: 5.532

Review 6.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

7.  In vivo sensitization of T cells to hapten-conjugated syngeneic structures of major histocompatibility complex. I. Effect of in vitro culture upon generation of cytotoxic T lymphocytes.

Authors:  A Starzinski-Powitz; K Pfizenmaier; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1976-11       Impact factor: 5.532

8.  Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide.

Authors:  P Debré; C Waltenbaugh; M E Dorf; B Benacerraf
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

9.  Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the generation of killer activity.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.

Authors:  M Röllinghoff; A Starzinski-Powitz; K Pfizenmaier; H Wagner
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  35 in total

1.  Evidence of a plasma-mediated "window" of immunodeficiency in rats following trauma.

Authors:  C D Mills; M D Caldwell; D S Gann
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

2.  Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.

Authors:  L S Stewart; H F Sewell; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

3.  Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.

Authors:  K Shiiba; R Suzuki; K Kawakami; A Ohuchi; K Kumagai
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 4.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

5.  Serum IL-2 inhibitor in mice. I. Increase during infection.

Authors:  R Lelchuk; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

6.  Interleukin 2 induction in Lyt 1+ 23- T cells from Listeria monocytogenes-immune mice.

Authors:  S H Kaufmann; H Hahn; M M Simon; M Röllinghoff; H Wagner
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

7.  Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders.

Authors:  J Y Djeu; T Kasahara; J E Balow; G C Tsokos
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

8.  Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients.

Authors:  G Semenzato; C Agostini; L Trentin; R Zambello; M Chilosi; A Cipriani; E Ossi; M R Angi; L Morittu; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

Review 9.  Natural and induced immunity to mouse mammary tumors and the mammary tumor virus (MuMTV).

Authors:  O Stutman
Journal:  Springer Semin Immunopathol       Date:  1982

10.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.